Education
About Us
Working with TipRanks
Follow Us
Synlogic (SYBX)
OTHER OTC:SYBX
SYBX Stock Chart & Stats
$1.22
$0.02(1.41%)
At close: 4:00 PM EST
$1.22
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.96
Previous CloseN/A
Volume234.00
Average Volume (3M)41.08K
Market Cap
$7.27M
Enterprise Value-$8.57M
Total Cash (Recent Filing)$15.59M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,698,919
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.34
Price to Sales (P/S)2134.34
P/FCF Ratio-0.54
Enterprise Value/Market Cap-1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda3.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity BaseA strong equity base without debt provides Synlogic with financial stability and flexibility, allowing it to invest in R&D and strategic initiatives without the burden of interest payments.
High Revenue GrowthHigh revenue growth indicates increasing demand for Synlogic's products, suggesting successful R&D efforts and potential market expansion, crucial for long-term success in biotechnology.
Strategic PartnershipsStrategic partnerships provide Synlogic with milestone payments and research funding, enhancing its R&D capabilities and accelerating the development of its Synthetic Biotic medicines.
Bears Say
Persistent LossesOngoing losses highlight operational inefficiencies and high costs, which could hinder Synlogic's ability to achieve sustainable profitability and limit its financial resources for growth.
Negative Cash FlowsNegative cash flows indicate cash consumption in operations, necessitating strategic cash management to ensure liquidity and fund ongoing R&D and operational activities.
Decreasing Total AssetsA decline in total assets could limit Synlogic's ability to invest in new projects and maintain competitive advantage, potentially impacting long-term growth and market position.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.96 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $7.27M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,698,919 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
0.37% Insiders
2.08% Mutual Funds
<0.01% Other Institutional Investors
96.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---